Sanofi: Press Releases, Monday, December 9, 2019
Appendices
List of Appendices
| Appendix 1 | R&D Pipeline |
| Appendix 2 | Expected R&D milestones |
| Appendix 3 Appendix 4 | Business Operating Income definition Free Cash Flow definition |
Appendix 1: R&D Pipeline
New Molecular Entities(*)
| Phase 1 (Total : 20) | Phase 2 (Total : 8) | Phase 3 (Total : 7) | Registration (Total : 2) | ||||
| SAR441344(**)(1) Anti-CD40L mAb Multiple Sclerosis | ST400(**)(5) Ex Vivo ZFN Gene-Edited Cell Therapy, Beta thalassemia | SAR440340(**)(11) Anti-IL33 mAb Atopic Dermatitis | SAR422459(**)(13) ABCA4 gene therapy Stargardt Disease | avalglucosidase alfa Neo GAA Pompe Disease | isatuximab Anti-CD38 mAb 3L RRMM (ICARIA) (U.S.,EU) | ||
| SAR408701 Maytansin-loaded anti-CEACAM5 mAb, NSCLC | BIVV003(**)(5) Ex Vivo ZFN Gene-Edited Cell Therapy, Sickle Cell Disease | romilkimab (SAR156597) Anti-IL4/IL13 bispecific mAb Systemic Scleroderma | SAR442168(**)(14) BTK inhibitor Multiple Sclerosis | venglustat Oral GCS inhibitor ADPKD(15) | SAR341402 (insulin aspart) Rapid acting insulin Type 1/2 Diabetes (EU) | ||
| SAR439459 anti-TGFb mAb Advanced Solid Tumors | BIVV020 Complement C1s inhibitor | R | olipudase alfa rhASM AS Deficiency(12) | HIV Viral vector prime & rgp120 boost vaccine | fitusiran RNAi targeting anti-thrombin Hemophilia A and B | ||
| O | REGN5458(**)(2) Anti-BCMAxCD3 bispecific mAb Relapsing Refractory MM | SAR443060(**)(6) RIPK1 inhibitor(7) Amyotrophic Lateral Sclerosis | SAR339375 miRNA-21 Alport Syndrome | SAR439859 SERD Metastatic Breast Cancer | sutimlimab Anti Complement C1s mAb Cold Agglutinin Disease | ||
| O | REGN4018(**)(2) Anti-MUC16xCD3 bispecific mAb Ovarian Cancer | SAR443122(**)(6) RIPK1 inhibitor(7) Systemic inflammatory diseases | BIVV001(**)(16) rFVIIIFc – vWF – XTEN(17) Hemophilia A | ||||
| SAR442720(**)(3) SHP2 inhibitor Solid Tumors | Next Gen PCV(**)(8) Pneumococcal Conjugate Vaccines | efpeglenatide(**)(18) Long-acting GLP-1 agonist Type 2 Diabetes | |||||
| SAR440234 T cell engaging multi spe mAb Leukemia | Herpes Simplex Virus Type 2(**)(9) HSV-2 therapeutic vaccine | nirsevimab(**)(19) Respiratory syncytial virus Monoclonal Antibody | |||||
| SAR441000(**)(4) Cytokine mRNA Solid tumors | Respiratory syncytial virus Infants 4-month and older Vaccines | ||||||
| SAR442085 Anti CD38 mAb Fc engineered Multiple Myeloma | SAR441169(**)(10) RORC (ROR gamma T) antagonist, Psoriasis | ||||||
| O | REGN5459(**)(2) Anti-BCMAxCD3 bispecific mAb Relapsing Refractory MM | SAR441236 Tri-specific neutralizing mAb HIV | |||||
| Immuno-inflammation | Rare Blood Disorders | Cardiovascular & metabolism | |||
| Oncology | MS & Neuro | Vaccines | |||
| Rare Diseases | Diabetes |
- Developed in collaboration with Immunext
- Regeneron product for which Sanofi has opt-in rights
- Developed in collaboration with Revolution Medicines
- Developed in collaboration with BioNtech
- Developed in collaboration with Sangamo
- Developed in collaboration with Denali
- Receptor-interacting serine/threonine-protein kinase 1
- Developed in collaboration with SK
- Developed in collaboration with Immune Design/Merck
- Developed in collaboration with Lead Pharma
- Developed in collaboration with Regeneron
- Acid Sphingomyelinase Deficiency also known as Niemann Pick type B
- Identification of out-licensing partner ongoing
- Developed in collaboration with Principia
- Autosomal Dominant Polycystic Kidney Disease
- Developed in collaboration with SOBI
- Recombinant Coagulation Factor VIII Fc – von Willebrand Factor – XTEN Fusion protein
- Developed in collaboration with Hanmi
- Developed in collaboration with AstraZeneca
O : Opt-in rights products for which rights have not been exercised yet
R : Registrational Study (other than Phase 3)
(*) Phase of projects determined by clinicaltrials.gov disclosure timing when relevant
(**) Partnered and/or in collaboration – Sanofi may have limited or shared rights on some of these products
mAb = monoclonal antibody; MM = Multiple Myeloma; RR = Relapsing Refractory; GCS = glucosylceramide synthase